Use of sodium‐glucose cotransporter‐2 inhibitors and risk of dementia: A population‐based cohort study
Main finding · Incident dementiaResult — go to the resultHazard ratio 0.74 95% CI 0.60–0.93Authors' conclusion
The use of SGLT-2i is associated with a decreased risk of dementia incidence in the study population in mainland China.
Study context
- Population
- T2D patients, new users of SGLT2i or DPP-4i, Yinzhou Regional Health Care Database, mainland China
- Participants
- 47,335 new users
- Exposure
- SGLT2i vs DPP-4i
- Outcome
- Incident dementia
Methodological detailstarget trial emulation, new-user design, inverse probability of treatment weighting
- Target trial emulation
- New-user design
- Inverse probability of treatment weighting
Main finding
As reported in the abstract
Hazard ratio
0.74
95% CI 0.60–0.93
By group
SGLT-2i
347.5 per 100 000 person-years
DPP-4i
500.2 per 100 000 person-years
SGLT-2ivs DPP-4i
HR 0.74 (95% CI 0.60–0.93)
Observational data: associations, not effects.
Further findings
- Results generally consistent in various subgroup and sensitivity analyses
Original publication
Use of sodium‐glucose cotransporter‐2 inhibitors and risk of dementia: A population‐based cohort study. Diabetes Obes Metab. Published 10 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →